Bliss GVS Pharma Limited
Momentum (100/100) does the heavy lifting; valuation (31/100) is the drag.
Buy zoneOvervaluedBliss GVS Pharma Limited earns a Hold from StocksWizard, with a blended score of 45/100. On 38.7x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹722.3. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. It clears 9 of 13 investability checks, with durability 70, valuation 61 and momentum 100 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹364.03.
1-year price
EOD · 2026-09-1452-week range
-0.19% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 11.6%
- Pass: Low debt (D/E < 0.5): 0.02x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 30%
- Pass: Earnings growing: 125%
- Pass: Net margin ≥ 10%: 13.9%
- Pass: Current ratio > 1.5: 4.02
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 13.55
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Shareholding
- Promoter57.5%
- Institutions6.7%
- Public & other35.8%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Trading near its 52-week high.
- Financially solid — Altman Z 13.55.
Opportunities
- Earnings growing (125% YoY).
- Revenue growing (30% YoY).
- Trading in our value buy zone versus sector peers.
Bear case
Weaknesses
- Weak Piotroski score (3/9).
Threats
- Trades ~37% above our estimated fair value.
About Bliss GVS Pharma Limited
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations across India and internationally. The company produces drugs across multiple therapeutic categories including anti-diabetic, anti-infective, anti-inflammatory, antifungal, cardiovascular, dermatological, gastrointestinal, neurological, ophthalmic, respiratory, and urological products, along with over-the-counter medications and supplements. It also provides pain management services and engages in pharmaceutical exports.
Bliss GVS Pharma Limited — frequently asked questions
Is Bliss GVS Pharma Limited a buy, hold or sell?
StocksWizard currently rates Bliss GVS Pharma Limited (BLISSGVS) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Bliss GVS Pharma Limited's fair value?
Our blended DCF and relative-valuation model estimates Bliss GVS Pharma Limited's fair value at about ₹455.03, versus a current price of ₹720.95 — roughly 37% downside. On that basis the stock looks overvalued by 37%.
Is Bliss GVS Pharma Limited financially healthy?
Bliss GVS Pharma Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Bliss GVS Pharma Limited's share price performed?
Bliss GVS Pharma Limited is up 64% over three months, and last traded at ₹720.95. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.